drugset / Trial / NCT06378047
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
Phase 1
Completed
2 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Angiodynamics, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART).
Timeline
- Start
- 2024-04-10
- Primary completion
- 2025-09-15
- Completion
- 2025-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |